Scarica l'app Stockscreener
3.50
2.78%
-0.10
Dopo l'orario di chiusura:
3.50
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Altimmune Inc Borsa (ALT) Ultime notizie
3 Explosive Stocks With High Short Interest - AOL.com
Altimmune: The High Cost Of Going Solo (Rating Downgrade) (NASDAQ:ALT) - Seeking Alpha
Altimmune at Barclays Conference: Advancing Pemvidutide’s Potential By Investing.com - Investing.com Canada
Altimmune Touts Pemvidutide Progress, Targets MASH Phase 3 Start and Q3 AUD Readout at Barclays Chat - Yahoo Finance
Aug Final Week: Is Altimmune Inc stock a value trap2026 Macro Impact & AI Driven Price Forecasts - baoquankhu1.vn
ALT (Altimmune) NonCurrent Deferred Revenue : $0.16 Mil (As of Dec. 2025) - GuruFocus
Altimmune (MEX:ALT1) NonCurrent Deferred Revenue : MXN2.88 Mil (As of Dec. 2025) - GuruFocus
Altimmune Details Pemvidutide MASH Path: Breakthrough Therapy, FDA Feedback, Phase 3 Next Up - MarketBeat
Altimmune at Leerink Conference: Strategic Advances in MASH Treatment By Investing.com - Investing.com Canada
ALT Stock Price, Quote & Chart | ALTIMMUNE INC (NASDAQ:ALT) - ChartMill
Altimmune Details Pemvidutide Phase III MASH Plans, Breakthrough Status at Citizens Conference - Yahoo Finance
Does Altimmune (ALT) have the potential to rally 229.28% as Wall Street analysts expect? - MSN
ALT stock drops on wider-than-expected Q4 loss: Retail voices hopes for deal to alleviate cash concerns - MSN
Altimmune at The Citizens Life Sciences Conference: Strategic Insights on Pemvidutide - Investing.com
ALT: Pemvidutide advances to phase 3, targeting MASH with strong efficacy and best-in-class tolerability - TradingView
Fireside chat set for Leerink Global Healthcare Conference, Altimmune announces - Traders Union
Altimmune Bets Big on PEMB as Phase III Nears - TipRanks
Altimmune to start late-stage trial for MASH candidate this year - MSN
Altimmune CFO Weaver buys $17,700 in shares By Investing.com - Investing.com Australia
Altimmune joins Citizens Life Sciences Conference for fireside chat in Miami Beach - Traders Union
Altimmune CEO Durso buys $70,790 in shares By Investing.com - Investing.com India
Gregory Weaver Acquires 5,000 Shares of Altimmune (NASDAQ:ALT) Stock - MarketBeat
Altimmune (NASDAQ:ALT) CEO Acquires $70,800.00 in Stock - MarketBeat
Altimmune Inc (ALT) CEO Jerome Durso Increases Stake with Recent Insider Purchase - GuruFocus
Altimmune CEO Durso buys $70,790 in shares - Investing.com
Altimmune CFO Weaver buys $17,700 in shares - Investing.com
Altimmune (NASDAQ: ALT) CEO buys 20,000 shares in open market - Stock Titan
Altimmune, Inc. (NASDAQ:ALT) Given Average Recommendation of "Hold" by Analysts - MarketBeat
ALT Stock Drops On Wider-Than-Expected Q4 Loss: Retail Voices Hopes For Deal To Alleviate Cash Concerns - Stocktwits
Can Altimmune Inc. stock deliver surprise earnings beat2026 Volume Leaders & Weekly High Return Stock Forecasts - Naître et grandir
Altimmune (NASDAQ:ALT) Rating Lowered to Sell at Wall Street Zen - MarketBeat
History Review: Is Altimmune Inc a speculative investment2025 Investor Takeaways & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
ALT: Analyst Lowers Price Target While Maintaining Buy Rating | - GuruFocus
Altimmune (NASDAQ:ALT) Price Target Cut to $13.00 by Analysts at B. Riley Financial - MarketBeat
Altimmune (NASDAQ:ALT) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Altimmune Reports FY25 Financials: Why Is Big Pharma Staying Away (NASDAQ:ALT) - Seeking Alpha
Altimmune, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
B. Riley Adjusts Price Target on Altimmune to $13 From $18, Maintains Buy Rating - marketscreener.com
Altimmune, Inc. (NASDAQ:ALT) Q4 2025 Earnings Call Transcript - Insider Monkey
Altimmune: Q4 Earnings Insights - Sahm
William Blair Maintains Market Perform on ALT (Altimmune, Inc.) March 2026 - Meyka
Altimmune Q4 Earnings Call Highlights - MarketBeat
Altimmune Inc (ALT) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Fortification - GuruFocus
Altimmune (ALT) Advances Liver Disease Focus with Pemvidutide - GuruFocus
Altimmune Stock Attracts Strong Retail Buzz As Investors Count Down To 48-Week Data For Its Fatty Liver Treatment - Stocktwits
William Blair reiterates Altimmune stock rating on trial data By Investing.com - Investing.com Nigeria
Altimmune Shares Fall After Q4 Results - marketscreener.com
William Blair reiterates Altimmune stock rating on trial data - Investing.com India
Altimmune Q4 2025 Earnings Call Transcript - MarketBeat
Altimmune (ALT) Shares Drop Despite Breakthrough Therapy Plans - GuruFocus
Altimmune (ALT) Q4 2025 Earnings Call Transcript - The Globe and Mail
Earnings call transcript: Altimmune Inc. misses Q4 2025 expectations, stock declines - Investing.com Nigeria
Altimmune Reports 2025 Financial Results and Clinical Trial Progress with New Partnerships Formed - geneonline.com
Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates - Bitget
Altimmune earnings missed by $0.02, revenue fell short of estimates - Investing.com
Altimmune (ALT) Reports Increased Revenue and Advances in Liver Disease Treatment - GuruFocus
ALTIMMUNE ($ALT) Releases Q4 2025 Earnings - Quiver Quantitative
Altimmune stock edges down on fourth quarter earnings miss By Investing.com - Investing.com UK
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):